{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:26:07Z","timestamp":1793989567631,"version":"4.8.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.euf.2025.12.001","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T22:48:51Z","timestamp":1765493331000},"page":"769-784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Metastatic Hormone-sensitive Prostate Cancer Treatments on Health-related Quality of Life: A Systematic Review and Network Meta-analysis"],"prefix":"10.1016","volume":"12","author":[{"given":"Tessa","family":"van Elst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurien M.","family":"Buffart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.E.","family":"Custers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieke","family":"Wever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jippe C.","family":"de Bie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.A.","family":"Mulders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiko J.","family":"Bloemendal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul A.","family":"van Basten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.12.001_b0005","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boeve","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.12.001_b0010","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.12.001_b0015","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.12.001_b0020","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.12.001_b0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.12.001_b0035","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.12.001_b0040","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2025.12.001_b0045","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.euf.2020.01.017","article-title":"Health-related quality of life in patients with advanced prostate cancer: a systematic review","volume":"7","author":"Kretschmer","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2025.12.001_b0050","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euf.2025.12.001_b0055","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.euf.2025.12.001_b0060","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singap"},{"key":"10.1016\/j.euf.2025.12.001_b0065","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","article-title":"Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system","volume":"13","author":"Yellen","year":"1997","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.euf.2025.12.001_b0070","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF00433915","article-title":"Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system","volume":"5","author":"Bonomi","year":"1996","journal-title":"Qual Life Res"},{"key":"10.1016\/j.euf.2025.12.001_b0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","article-title":"Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes","volume":"273","author":"Wilson","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.euf.2025.12.001_b0080","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1477-7525-10-134","article-title":"Systematic review of health-related quality of life models","volume":"10","author":"Bakas","year":"2012","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.euf.2025.12.001_b0085","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1547-5069.2005.00058.x","article-title":"Conceptual model of health-related quality of life","volume":"37","author":"Ferrans","year":"2005","journal-title":"J Nurs Scholarsh"},{"key":"10.1016\/j.euf.2025.12.001_b0090","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41391-023-00668-0","article-title":"Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy","volume":"27","author":"Afferi","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euf.2025.12.001_b0095","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euf.2025.12.001_b0100","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1741-7015-11-159","article-title":"Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers","volume":"11","author":"Jansen","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.euf.2025.12.001_b0105","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.euf.2025.12.001_b0110","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1002\/sim.6001","article-title":"Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons","volume":"32","author":"Konig","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.euf.2025.12.001_b0115","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"Rucker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.euf.2025.12.001_b0120","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2025.12.001_b0125","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2025.12.001_b0130","unstructured":"Sterne JA, Mathur MB, Elbers R, et al. The Risk Of Bias In Non-randomized Studies \u2013 of Interventions, Version 2 (ROBINS-I V2) assessment tool. 2024."},{"key":"10.1016\/j.euf.2025.12.001_b0135","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.euo.2022.04.007","article-title":"Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment","volume":"5","author":"Menges","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0140","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074495","article-title":"A guide and pragmatic considerations for applying GRADE to network meta-analysis","volume":"381","author":"Izcovich","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2025.12.001_b0145","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.euf.2025.12.001_b0150","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.eururo.2020.08.023","volume":"79","author":"Boeve","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.12.001_b0155","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0160","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2017.75.3335","article-title":"Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer","volume":"36","author":"Morgans","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0165","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.21.00728","article-title":"Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial","volume":"40","author":"Rush","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0170","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.eururo.2020.03.019","article-title":"Effect of enzalutamide plus androgen deprivation therapy on health-related quality of life in patients with metastatic hormone-sensitive prostate cancer: an analysis of the ARCHES randomised, placebo-controlled, phase 3 study","volume":"78","author":"Stenzl","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.12.001_b0175","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.21.00941","article-title":"Health-related quality of life in metastatic, hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international, randomized phase III trial led by ANZUP","volume":"40","author":"Stockler","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0180","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(19)30620-5","article-title":"Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study","volume":"20","author":"Agarwal","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0185","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0190","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12032-021-01480-3","article-title":"Short-term outcomes of risk-adapted upfront docetaxel administration in patients with metastatic hormone-sensitive prostate cancer: a multicenter prospective study in Japan","volume":"38","author":"Muto","year":"2021","journal-title":"Med Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0195","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.euo.2023.01.001","article-title":"Adverse events and androgen receptor signaling inhibitors in the treatment of prostate cancer: a systematic review and multivariate network meta-analysis","volume":"6","author":"Cao","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0200","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41391-019-0195-5","article-title":"A review of prostate cancer treatment impact on the CNS and cognitive function","volume":"23","author":"Ryan","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7_Suppl","key":"10.1016\/j.euf.2025.12.001_b0205","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1200\/JCO.2019.37.7_suppl.156","article-title":"Higher blood\u2013brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography","volume":"37","author":"Zurth","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0210","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12325-019-01157-4","article-title":"Matching-adjusted indirect comparison of health-related quality of life and adverse events of apalutamide versus enzalutamide in non-metastatic castration-resistant prostate cancer","volume":"37","author":"Chowdhury","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.euf.2025.12.001_b0215","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.euo.2024.02.009","article-title":"A prospective randomised trial to determine the effect of a reduced versus standard dose of enzalutamide on side effects in frail patients with prostate cancer","volume":"7","author":"Boerrigter","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0220","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2022.04.034","article-title":"Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: a randomised clinical trial (HEAT)","volume":"171","author":"Ternov","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euf.2025.12.001_b0225","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.urology.2016.02.010","article-title":"Practical guidance on the role of corticosteroids in the treatment of metastatic castration-resistant prostate cancer","volume":"96","author":"De Santis","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.euf.2025.12.001_b0230","article-title":"Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis","volume":"12","author":"Jakob","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 2","key":"10.1016\/j.euf.2025.12.001_b0235","doi-asserted-by":"crossref","first-page":"S1339","DOI":"10.1016\/j.eururo.2025.09.3708","volume":"87","author":"Saad","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.12.001_b0240","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41391-022-00529-2","article-title":"Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer-exploratory analysis of LATITUDE study","volume":"26","author":"Roy","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euf.2025.12.001_b0245","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.gerinurse.2022.12.015","article-title":"Self-reported pain and fatigue are associated with physical and cognitive function in middle to older-aged adults","volume":"50","author":"Peterson","year":"2023","journal-title":"Geriatr Nurs"},{"key":"10.1016\/j.euf.2025.12.001_b0250","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/PSY.0b013e3182294a50","article-title":"The nocebo effect and its relevance for clinical practice","volume":"73","author":"Colloca","year":"2011","journal-title":"Psychosom Med"},{"key":"10.1016\/j.euf.2025.12.001_b0255","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(18)30780-0","article-title":"Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study","volume":"20","author":"Downing","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0260","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00432-008-0409-z","article-title":"Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study","volume":"134","author":"Arai","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0265","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12325-018-0861-3","article-title":"Patient preferences for metastatic hormone-sensitive prostate cancer treatments: a discrete choice experiment among men in three European countries","volume":"36","author":"de Freitas","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.euf.2025.12.001_b0270","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40271-023-00638-7","article-title":"Discrete-choice experiment to understand the preferences of patients with hormone-sensitive prostate cancer in the USA, Canada, and the UK","volume":"16","author":"Gonzalez","year":"2023","journal-title":"Patient"},{"key":"10.1016\/j.euf.2025.12.001_b0275","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.euros.2023.03.001","article-title":"Patient and general population preferences regarding the benefits and harms of treatment for metastatic prostate cancer: a discrete choice experiment","volume":"51","author":"Menges","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euf.2025.12.001_b0280","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bju.15507","article-title":"Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis","volume":"129","author":"Mori","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.12.001_b0285","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jamaoncol.2020.6973","article-title":"Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0290","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102441","article-title":"Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis","volume":"110","author":"Fallara","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euf.2025.12.001_b0300","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/annonc\/mdy071","article-title":"What is the optimal systemic treatment of men with metastatic, hormone-na\u00efve prostate cancer? A STOPCAP systemic review and network meta-analysis","volume":"29","author":"Vale","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0305","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2024.42.4_suppl.118","article-title":"Interaction of age and benefit of treatment intensification in advanced prostate cancer: an aggregate meta-analysis of 14 randomized trials","volume":"42","author":"Morgans","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.euf.2025.12.001_b0310","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2025.43.5_suppl.20","article-title":"Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD)","volume":"43","author":"Fisher","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0315","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1464-410X.2010.09861.x","article-title":"Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study","volume":"107","author":"Thong","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.12.001_b0320","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0325","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0330","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/JU.0000000000001841","article-title":"Apalutamide plus androgen deprivation therapy for metastatic castration-sensitive prostate cancer: analysis of pain and fatigue in the phase 3 TITAN study","volume":"206","author":"Agarwal","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.12.001_b0335","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jjco\/hyy129","article-title":"Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study","volume":"48","author":"Fukasawa","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0340","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/jjco\/hyaa030","article-title":"Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study","volume":"50","author":"Suzuki","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.001_b0345","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/pros.24396","article-title":"The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups","volume":"82","author":"Stenzl","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.euf.2025.12.001_b0350","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41416-023-02492-8","article-title":"Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN","volume":"130","author":"Shen","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euf.2025.12.001_b0355","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/iju.14843","volume":"29","author":"Uemura","year":"2022","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2025.12.001_b0360","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/iju.14447","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: a subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study","volume":"28","author":"Uemura","year":"2021","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2025.12.001_b0365","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925003529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925003529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:51:02Z","timestamp":1793987462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925003529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2405456925003529"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.12.001","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Metastatic Hormone-sensitive Prostate Cancer Treatments on Health-related Quality of Life: A Systematic Review and Network Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}